ClinicalTrials.gg

Program

encoberminogene rezmadenovec

Also written as “XC001” and “AdVEGFXC1”.

Its studies are mostly in Coronary Artery Disease · Angina Pectoris, led by XyloCor Therapeutics.

Furthest: phase 2, since Oct 4, 20193 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
XyloCor Therapeutics32 open or runningphase 2since Oct 4, 2019Oct 4, 2019Dec 30, 2026phase 2 · NCT07118449

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 4, 2019First study: phase 2 study in Coronary Artery DiseaseFirst studyNCT04125732 · 41 enrolled · United States
  2. Jun 24, 2025Phase 2 study in Angina PectorisNCT07048808 · 106 planned · United States
  3. Jul 17, 2025Phase 2 study in Coronary Artery DiseaseNCT07118449 · 116 planned · United States

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in Coronary Artery DiseaseNCT07118449
  2. Jun 30, 2027Primary completion: phase 2 study in Angina PectorisNCT07048808

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07118449Coronary Artery Disease · United States2Not yet recruitingDec 30, 2026116
NCT07048808Angina Pectoris · United States2RecruitingJun 30, 2027106
NCT04125732Coronary Artery Disease · United States2CompletedJan 31, 202341

How it is read

Names in the registry

  • “XC001”, 2 entries
  • “AdVEGFXC1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.